EUVIMEDEUVIMED entdecken
Crossref

Change of initial oral antidiabetic therapy in type 2 diabetic patients

Arian Plat, Fernie Penning-van Beest, Sophia Kessabi, Martijn Groot, Ron Herings

Pharmacy World & Science · 2009-12 · 31 (6) · 622-626

DOI: 10.1007/s11096-009-9321-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy World & Science, online erschienen am 20.08.2009. Verfasst von Arian Plat und 4 weiteren Autor:innen. Beteiligte Einrichtung: PHARMO Institute, Utrecht, The Netherlands. arian.plat@pharmo.nl. Hauptthemen laut MEDLINE: Practice Patterns, Physicians'. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To explore the 'real-life' therapy of type 2 diabetes mellitus with oral antidiabetic drugs (OADs). METHODS: From the PHARMO Record Linkage System comprising linked drug dispensing and clinical laboratory data from approximately 2.5 million individuals in the Netherlands, among others, new users of OADs were identified in the period 1999-2004. New users, aged 30 years and older, without insulin use before cohort entry date and with at least one year follow-up were included. We determined per initial therapy patient characteristics and first therapy change. RESULTS: Overall 35,514 patients were included. Metformin and sulfonylureas (SU) were the most frequent initial therapy. Patients on thiazolidinedione (TZD) monotherapy had lower percentages baseline HbA1c >or= 7% compared to patients on metformin and SU. The proportion of patients still on initial therapy after one year ranged from 46% (TZDs) to around 60% (SU). Among patients starting on monotherapy, add-on (15-20%) and discontinuation (16-25%) of therapy occurred most frequently. In patients starting on combination therapy, a switch occurred in 30% of the patients. CONCLUSION: In more than 40% of the patients a change in initial OAD-therapy is already observed in the first year of therapy. Maintaining patients on initial therapy remains a challenge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Practice Patterns, Physicians'Administration, OralAdultAgedBiomarkersDiabetes Mellitus, Type 2Drug Administration ScheduleDrug Therapy, CombinationDrug UtilizationFemaleGlycated HemoglobinHumansHypoglycemic AgentsMaleMedical Records Systems, ComputerizedMiddle AgedNetherlandsRetrospective StudiesTime FactorsTreatment Outcome

Substanzen

BiomarkersGlycated HemoglobinHypoglycemic Agentshemoglobin A1c protein, human

Autor:innen und Institutionen

  • PHARMO Institute, Utrecht, The Netherlands. arian.plat@pharmo.nl

Zitieren

APA

Plat, A., Penning-van Beest, F., Kessabi, S., Groot, M., & Herings, R. (2009). Change of initial oral antidiabetic therapy in type 2 diabetic patients. Pharmacy World & Science, 31(6), 622-626. https://doi.org/10.1007/s11096-009-9321-0

Vancouver

Plat A, Penning-van Beest F, Kessabi S, Groot M, Herings R. Change of initial oral antidiabetic therapy in type 2 diabetic patients. Pharmacy World & Science. 2009;31(6):622-626. doi:10.1007/s11096-009-9321-0

BibTeX
@article{Plat2009,
  author = {Plat, Arian and Penning-van Beest, Fernie and Kessabi, Sophia and Groot, Martijn and Herings, Ron},
  title = {Change of initial oral antidiabetic therapy in type 2 diabetic patients},
  journal = {Pharmacy World & Science},
  year = {2009},
  volume = {31},
  number = {6},
  pages = {622--626},
  doi = {10.1007/s11096-009-9321-0}
}
Kostenlos starten →